Articles tagged with Schizophrenia
A new clinical discussion tool, GAIN, has been developed to help physicians discuss potential reasons for using long-acting injectable antipsychotic therapies with patients. The tool addresses barriers such as needle phobia and stigma, aiming to increase patient acceptance and adherence.
Researchers found no significant increase in violent crime among people with schizophrenia, contrary to previous assumptions. The study suggests that substance abuse co-occurring with schizophrenia is a key factor contributing to violence.
A study published in JAMA found that substance abuse increases the risk of violent crime in individuals with schizophrenia, with a 4.4-fold increased risk for those with comorbid substance abuse. The study also suggests that current practice for violence risk assessment and management may need review.
New studies demonstrate RISPERDAL CONSTA (risperidone) Long-Acting Treatment significantly improves clinical and functional outcomes for patients with schizophrenia. The treatment reduced rates of rehospitalization among patients, especially those with complex medical histories.
Researchers found significant cognitive problems exist in first-episode schizophrenia, affecting work, study, and social life. Early diagnosis may aid treatment and improve prognosis.
Researchers have identified a previously unknown form of potassium channel, Isoform 3.1, implicated in schizophrenia and linked to abnormal brain activity. Inhibiting this protein may correct disorganized brain activity without cardiac side effects associated with existing antipsychotic medications.
Researchers have identified a genetic variant that impairs communication within the brain, increasing the risk of schizophrenia and manic depression. The study found altered brain activity patterns, particularly between the dorsolateral prefrontal cortex and other regions.
The Medical College of Georgia is part of a large national study examining the genes of 10,000 patients with schizophrenia and 10,000 healthy individuals. The study aims to pinpoint variations that can improve disease diagnosis and treatment.
Scientists have discovered a compound that selectively targets the M1 receptor, implicated in diseases like AD and schizophrenia. This finding holds promise for developing an effective treatment with minimal side effects.
A study by Nicole Lauzon and Dr. Steven Laviolette found specific receptors in the brain can control emotional significance and memory formation for traumatic events, offering new therapeutic treatments for psychiatric disorders like Schizophrenia and PTSD.
A specific DNA change has been identified as a potential mechanism for developing schizophrenia. The research found that the altered gene increases expression in cells grown in culture, echoing findings in postmortem brain samples from individuals with schizophrenia.
Patients with schizophrenia can correctly identify a 'hollow mask' illusion, which may be related to their brains disconnecting visual information from internal thoughts. The study also found that cannabis users are less deceived by the illusion, suggesting a possible link between THC and brain connectivity.
Researchers discovered a significant link between schizophrenia and type 2 diabetes in a study of 50 people newly-diagnosed with schizophrenia. The study found that 16% of participants had either diabetes or abnormal glucose metabolism rates.
Researchers have identified a connection between daily cannabis consumption and the appearance of psychosis and schizophrenia in subjects with good premorbid performance. The study found that 66% of patients with normal neurodevelopment admitted to daily cannabis use, while 43% of those with abnormal neurodevelopment also used cannabis.
A study by MIT researchers found that inhibiting a key brain enzyme in mice reversed schizophrenia-like symptoms, offering potential new drug treatments. The discovery provides insight into the DISC1 gene's role in regulating GSK3B activity and its impact on neural stem cells.
Scientists at the University of Leeds have discovered a link between toxoplasmosis and schizophrenia, suggesting that the parasite affects dopamine production in the brain. The study provides new insights into the development of schizophrenia and its potential connections to other neurological disorders.
Researchers identified 49 genes involved in cell-to-cell signalling in the brains of schizophrenia patients compared to controls, supporting the theory that faulty signalling is involved in the disease. The findings could lead to new ways of diagnosing and treating the condition.
Researchers will map planum temporale's functional organization to better understand its role in language abilities and disorders. The study aims to find connections between the brain region and conditions such as autism, schizophrenia, and perfect pitch.
Researchers discovered that mice lacking neuregulin develop dendritic spine abnormalities and exhibit hallmarks of schizophrenia, supporting the hypothesis that glutamatergic neurons play a crucial role. The study suggests that developmental defects in brain structure may contribute to schizophrenia's onset.
A UK survey found that only 30% of mental health workers discuss sexual health issues with service users, despite 80% agreeing it's an important part of their role. The study also revealed low levels of awareness about HIV risks among people with schizophrenia, leading to concerns about infection rates and staff safety.
A new study reveals that large structural DNA changes, known as copy number variants, may be responsible for schizophrenia. Researchers found eight deletions in patients' genomes, two of which were newly identified, suggesting that these rare variations could be causative.
Schizophrenia can be detected early by identifying physical markers in the brain, according to Prof. Talma Hendler's groundbreaking work on facial recognition and brain imaging. By analyzing brain activity in response to unusual emotional faces, researchers hope to develop more effective treatments.
Researchers identified three genetic variants associated with delusions in people with schizophrenia, located within the neuregulin 3 gene on chromosome 10. The study suggests that this gene may contribute to the development of delusions and other symptoms of the condition.
Research suggests that schizophrenia patients' reduced non-verbal expressivity is linked to poor social skills and an inability to accurately imagine others' thoughts and feelings. This impairment contributes to difficulties in conversation and social interactions, making it challenging for people with schizophrenia to engage with others.
A new MIT study found that schizophrenia is linked to an overactive 'default mode' brain system involved in self-reflection. This hyperactive system causes patients to have an exaggerated focus on themselves, leading to cognitive and psychological symptoms.
A global study reveals that people with schizophrenia experience and expect significant discrimination in various aspects of life, including employment, relationships, and social interactions. The study, which analyzed data from 27 countries, found that negative experienced discrimination was common across all domains.
A large-scale study of 9 million Swedish individuals reveals that bipolar disorder and schizophrenia share common genetic causes, with heritability rates of 64% and 59%, respectively. This finding challenges the long-held distinction between the two conditions, suggesting a reappraisal of their diagnostic entities.
Research suggests that autism and schizophrenia may stem from similar physical abnormalities caused by disruptions in early organogenesis, typically between 20-40 days after fertilization. This developmental stage is critical in shaping the body's development, and errors during this period can lead to various mental health disorders.
Researchers identified a faulty brain circuit and developed an experimental agent that improves working memory and EEG signals in people with schizophrenia. The study found the drug MK-0777 to be well-tolerated, but further trials are needed to verify its value.
Elevated levels of kynurenic acid in the brain have been linked to problem-solving deficits in patients with schizophrenia. The finding suggests that drugs targeting this compound could be used to treat cognitive impairments associated with the disorder.
A collaborative study reveals how interactions between common gene variants affect brain function in schizophrenia patients, particularly in working memory. The findings suggest that combining these genetic variations may lead to reduced cortical activity, making them potential new targets for treatments.
Researchers at the University of Pittsburgh have identified the orbitofrontal cortex as a promising target for developing new antipsychotic drugs to treat schizophrenia. The study found that this brain region responds to both dopamine and glutamate, neurotransmitters linked to schizophrenia.
Research suggests that cerebral inflammation and microglia activation contribute to schizophrenia development. Anti-inflammatory agents targeting activated microglia may provide a new treatment option for the condition.
Researchers at Newcastle University have identified a key brain link that causes schizophrenia, revealing NMDA receptors play a critical role in modifying brain oscillations. Optimizing receptor function could lead to new treatment approaches for the mental illness, affecting one in 100 people.
Research suggests that birth hypoxia may contribute to the development of schizophrenia by reducing brain-derived neurotrophic factor (BDNF) levels. The study found a significant decrease in BDNF among individuals who later developed schizophrenia, highlighting the importance of maternal health during pregnancy.
Researchers found that deleting the gene for glutamate transporter EAAT1 leads to increased responses to NMDA receptor antagonist MK-801, resulting in schizophrenia-like features in mice. The study suggests a promising new class of glutamate-targeting antipsychotic treatments may help correct these abnormalities.
Researchers have identified three new candidate genes for schizophrenia that may contribute to a better understanding of the disease. These genes are associated with brain function and are present in only 1% of schizophrenia patients, suggesting they play a significant role in its development.
NARSAD recognizes six scientists whose groundbreaking research has led to significant strides in understanding and treating mental illness. The 2008 prize winners include experts in schizophrenia, bipolar disorder, depression, childhood disorders, and cognitive neuroscience.
Researchers found that brain-derived neurotrophic factor (BDNF) levels can indicate impending relapse in schizophrenia patients. BDNF levels may drop even before symptoms worsen, suggesting a potential biomarker for early intervention and treatment adjustment.
A new study found that newer atypical antipsychotic medications were not more effective than an older conventional antipsychotic in treating child and adolescent schizophrenia. The study also revealed potential metabolic side effects, particularly with olanzapine, which may lead to serious health issues.
Research suggests that brain immaturity, specifically in the dentate gyrus region, may contribute to schizophrenia. This underdeveloped area affects working memory and mood regulation., The findings imply a potential biomarker for diagnosing and treating schizophrenia.
A survey of 200 community-based schizophrenic patients found that 74.5% were treated with off-label medication, with the most common combination being an antipsychotic and mood stabilizer. The study highlights the limitations of first- and second-generation antipsychotics and the need for improved treatment outcomes.
Researchers at Johns Hopkins University have uncovered a molecular circuitry associated with schizophrenia, linking three previously known proteins. The study found that these proteins interact synergistically during normal brain development and are linked to the condition in some patients.
A recent study published in Social Science and Medicine found that while Americans believe mental illness has a genetic cause, this has not led to increased tolerance for people with mental illness. Genetic arguments are associated with fears regarding violence for schizophrenia but social acceptance for depression.
A study published in BMC Psychiatry found that pregnant women experiencing severe stress during the second month of pregnancy are more likely to have children who develop schizophrenia. Women born in Jerusalem during the Arab-Israeli war had a higher risk of schizophrenia, particularly females.
Research found pregnant women experiencing high psychological stress are more likely to give birth to a child with schizophrenia. The study, which analyzed data from 88,829 people born in Jerusalem between 1964 and 1976, discovered a significantly higher incidence of schizophrenia among females.
Research suggests that schizophrenia may be a by-product of human brain evolution, driven by increased metabolic demands. The study found molecular mechanisms involved in the evolution of human cognitive abilities and identified changes in gene expression and metabolite concentrations in both healthy humans and individuals with schizop...
A randomized, double-blind study involving 102 women with schizophrenia found that estrogen estradiol improved psychotic symptoms more effectively than antipsychotic medications alone. No significant difference was observed in negative symptoms, suggesting potential for longer-term treatment or alternative approaches.
Research at Karolinska Institutet found that people with schizophrenia have an increased number of unusual chromosomal changes, particularly structural changes that can alter gene function. These changes, known as copy number variants, may contribute to the development of the disorder.
Researchers have identified four mutated gene regions linked to schizophrenia, offering new hope for treatment and diagnosis. The findings may lead to individualized medicine and earlier identification of those at risk.
A multinational study has discovered that people with schizophrenia are more likely to carry rare chromosomal structural changes, particularly those altering gene function. Two new genomic areas have been identified as significantly increasing the risk of developing the disease.
Researchers discovered a significant increase in rare deletions and duplications of genetic material in people with schizophrenia, affecting 13.1% of cases and 10.4% of controls. Two new sites on Chromosomes 1 and 15 were implicated as potent risk factors for the disorder.
Researchers have made a groundbreaking discovery in schizophrenia research, identifying three microdeletions and several single nucleotide polymorphisms that contribute to the illness. These genetic variations increase disease risk, with one of the microdeletions found on chromosome 1 having a moderate to large impact.
Researchers at Queen's University Belfast aim to discover improved treatments for nicotine dependence and symptoms of schizophrenia. The three-year fellowship will investigate the effects of nicotine and withdrawal on response inhibition and brain activity in smokers with and without schizophrenia.
A study published in Biological Psychiatry found that individuals with schizophrenia and bipolar disorder share a core set of genes involved in nervous system development and cell death. This common genetic signature may provide a window into discovering new brain mechanisms and effective treatments for these debilitating conditions.
A recent study published in Biological Psychiatry found four chromosomal regions linked to schizophrenia and bipolar disorder risk factors, suggesting that these disorders may represent different genetic subtypes. The discovery highlights the complexity of psychiatric diagnoses and provides new insights into potential treatment targets.
A disturbed cleavage of the Nrg-1 protein is connected with the development of schizophrenia and other psychiatric disorders. This discovery provides a new step forward in improved diagnosis and targeted treatment of the disease.
The NIMH CNTRICS Initiative aims to improve schizophrenia treatment by defining cognitive processes and neural circuits. Cognitive neuroscience insights are being translated into better treatments for impaired cognition in schizophrenia.
Researchers found a protein marker for schizophrenia risk in immune cells, with alpha defensin levels significantly elevated in patients and discordant twin pairs. This discovery could lead to the development of a simple blood test to evaluate schizophrenia risk.
A University of Pittsburgh School of Medicine study found that individuals with schizophrenia have lower levels of a key neurotransmitter GABA, which is impaired by the activation of the cannabinoid 1 receptor activated by marijuana. This impairment worsens cognitive symptoms and may lead to new drug targets for improved treatments.